PCSK9 inhibitors: The breakthrough lipid-lowering treatment at real-life setting – A 2-year regional lipid clinic experience Georgia Anastasiou, George Liamis, Haralampos Milionis, Moses Elisaf, Eliza Christopoulou, Theodora Dimitriou, Evangelos N. Liberopoulos
Pharmacological management of nonalcoholic fatty liver disease: Limitations, challenges and new therapeutic opportunities Eleni A. Karavia, Kyriakos E. Kypreos
The role of lipid-lowering treatment in the secondary prevention of ischemic stroke Eirini Konstantinidou, Konstantinos Tziomalos
The cardioprotective effects of flavonoids: a focus on classic cardiovascular risk factors Eleni Kokkou, Nikoleta Bozini, Maria Lavda, Konstantinos Mourouzis, Gerasimos Siasos
Pathophysiological mechanisms of dyslipidemia in patients with nephrotic syndrome: A fresh look M.S. Elisaf, S. Filippas-Ntekouan
Endothelial dysfunction in heart failure: The role of statins Evangelos Oikonomou, Gerasimos Siasos, Christina Chrysohoou, Dimitris Tousoulis
Europe to US: Re-establish specific low density lipoprotein cholesterol targets because we all need them Vasilios G. Athyros, Konstantinos Tziomalos, Asterios Karagiannis
Effects of monotherapy with high-dose rosuvastatin compared with the combination of low-dose rosuvastatin with fenofibrate or n-3 fatty acids on non-lipid serum parameters in patients with severe mixed dyslipidemia AP. Agouridis, TD. Filippatos, MS. Kostapanos, V. Tsimihodimos, DP. Mikhailidis, AD. Tselepis, MS. Elisaf
Inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9) A new approach to lipid lowering treatment E. Klouras, E. Liberopoulos, M. Elisaf